Biogen - Alzheimer's drug Aduhelm ... wow, what a problem !Guess Knight/EXELON wont have issues with Biogen's Alzheimer's drug in LATAM ... ever ! IMO
Biogen has lost all share price gains from the FDA approval ... and then some !
--------------------
Roughly 40% of early Alzheimer's patients taking Aduhelm in phase 3 studies were hit with a known side effect of the drug called amyloid-related imaging abnormalities, or ARIA.
(swelling - fluids)
---------------
A European Medicines Agency panel voted against approval of Biogen Inc's (BIIB.O) Alzheimer's drug Aduhelm, in another blow to prospects for a treatment already grappling with a slow rollout in the United States.
---------------
None of the 25 large insurers that responded to a Bloomberg News survey judged the $56,000-a-year drug “medically necessary,” a term used to describe treatments that are needed for specific ailments and meet medical standards. Most have deemed Aduhelm experimental, while some say they’re still evaluating it.
--------------
Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use.
----------------